| Dr. Kelley received his doctorate in chemistry from the University of Illinois at Urbana-Champaign under the direction of Jonathan Sweedler, performing elucidation and characterization of novel conotoxins and other neurotoxic and neuromodulatory peptide/protein natural products. He has worked at GSK for more than 20 years in pharmaceutical and biopharmaceutical R&D. He is currently a Director and Senior Fellow in Analytical Development and manages a group of late-phase, analytical work stream leaders that are accountable for all CMC analytical deliverables and regulatory authoring for biopharmaceutical assets from candidate selection through commercialization. Additionally, he has been involved in shaping analytical strategy including implementing platform and prior knowledge as well as leading due-diligence efforts and the biopharmaceutical product specification strategy. |
